23

Aug2017
PDCI has now published its information sharing webpage which aggregates submissions made by individuals and organizations in response to Health Canada’s Consultation on Proposed Amendments to the Patented Medicines Regulations. Click Here to Visit PDCI’s Information Sharing Webpage. The submissions have been provided by individuals & organizations on a completely voluntary ... Read More

22

Aug2017
***Participation Requested*** Sharing Responses to Health Canada’s Consultation on Proposed Amendments to the Patented Medicines Regulations In May 2017, Federal Minister of Health Jane Philpott, launched a consultation on proposed amendments to the Patented Medicines Regulations that would have significant effects on how patented ... Read More

30

May2017
Consultation on Potential Changes to the Patented Medicines Regulations On May 16, 2017, the Honourable Jane Philpott, Minister of Health, outlined a comprehensive plan for improving the pharmaceutical system in Canada. Included in the plan was the launch of a consultation process on potential changes to the Patented Medicines Regulations (Regulations) ... Read More

25

May2017
On Tuesday, May 16, 2017, Federal Health Minister Hon. Jane Philpott opened consultations on a suite of amendments to the Patented Medicines Regulations that will have significant effects on how patented drug prices are regulated in Canada. The implementation of these proposed amendments could represent the most important changes in ... Read More

16

May2017
Health Minister Hon. Jane Philpott Announces Consultations on proposed changes to the Patented Medicines Regulations Speaking today at the Economic Club of Canada in Ottawa, Federal Health Minister Jane Philpott announced the opening of a consultation period concerning proposed changes to the Patented Medicines Regulations that would have significant effects ... Read More

19

Apr2017
The new PMPRB Meds Entry Watch annual publication explores the market entry dynamics of new drugs launched in Canada and other international markets. This first edition of the report provides both a retrospective analysis of the new drugs launched over a six-year period from 2009 to 2014, and an early ... Read More

17

Feb2017

PMPRB Form 3 Reminder

This is a reminder to all patentees of their filing requirements to the PMPRB respecting revenues and research and development expenditures. All patentees must submit their Form 3 information for 2016 by March 1, 2017. These filing requirements are contained in section 5 of the Patented Medicines Regulations. As part of their ... Read More

02

Dec2016
As a first step to framework modernization, the Patented Medicines Prices Review Board (PMPRB) is undertaking major consultations regarding possible reform of its Compendium of Policies, Guidelines and Procedures, commonly referred to as “the Guidelines.” During Phase 1 of this consultation initiative, the PMPRB asked for input on how to rethink ... Read More

23

Nov2016
The Patented Medicine Prices Review Board (PMPRB) announced the reappointment of Dr. Mitchell Levine of Hamilton, Ontario as Vice-chairperson of the Board for a second five-year term. Dr. Levine is a Professor in the departments of Medicine and Clinical Epidemiology and Biostatistics in the Faculty of Health Sciences at McMaster ... Read More

26

Aug2016
Information Session on the PMPRB Guidelines Modernization Discussion Paper On August 23rd, 2016, PDCI Market Access Inc., Canada’s leading pricing and reimbursement consultancy, held a free “Information Session on the PMPRB Guidelines Modernization Discussion Paper”. This came shortly after the PMPRB recently releasing its long awaited consultation paper “PMPRB ... Read More